Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

Apellis Pharmaceuticals (United States)

apellis.comROR OpenAlex
World rank, 2022-now
#22,112
of 22,385
Rank in United States
#3,286
of 3,332
Research works
90
▲ 245% vs 2018-21
Citations
814
9.1 per fractional work
Top-10% rate
14.0%
all institutions 10.0%
vs its own fields
1.00×
1.00× is exactly expected
Open access
54%
world 40%
International
34%
world 18%
Apellis Pharmaceuticals (United States)

Which fields of science does Apellis Pharmaceuticals (United States) work in?

In 2022-now, 56% of research at Apellis Pharmaceuticals (United States) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (54%), Immunology and Microbiology (22%), Biochemistry, Genetics and Molecular Biology (8%). It does 2.2× the world's share of Health Sciences.

Health Sciences: 37 fractional works · 56.5% of its workMedicine: 35 fractional works · 53.9% of its workGenetics: 6 fractional works · 9.7% of its workHematology: 6 fractional works · 9.6% of its workOphthalmology: 4 fractional works · 6.7% of its workNephrology: 3 fractional works · 4.7% of its workHepatology: 2 fractional works · 3.0% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 2.7% of its workEpidemiology: 2 fractional works · 2.6% of its workNeurology: 2 fractional works · 2.5% of its workPulmonary and Respiratory Medicine: 1 fractional works · 1.9% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 1.7% of its workTransplantation: 1 fractional works · 1.5% of its workPathology and Forensic Medicine: 1 fractional works · 1.0% of its workOncology: 1 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 0.8% of its workInfectious Diseases: 0 fractional works · 0.7% of its workPhysiology: 0 fractional works · 0.6% of its workBiochemistry: 0 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.5% of its workImmunology and Allergy: 0 fractional works · 0.4% of its workSurgery: 0 fractional works · 0.3% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.2% of its workPharmacology: 0 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 1.1% of its workHealth Professions: 2 fractional works · 2.4% of its workRadiological and Ultrasound Technology: 2 fractional works · 2.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workDentistry: 0 fractional works · 0.2% of its workLife Sciences: 21 fractional works · 32.3% of its workImmunology and Microbiology: 14 fractional works · 21.8% of its workImmunology: 14 fractional works · 21.5% of its workVirology: 0 fractional works · 0.2% of its workBiochemistry, Genetics and Molecular Biology: 5 fractional works · 8.2% of its workMolecular Biology: 3 fractional works · 4.6% of its workPhysiology: 1 fractional works · 1.2% of its workBiotechnology: 1 fractional works · 0.8% of its workGenetics: 0 fractional works · 0.8% of its workCell Biology: 0 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNeuroscience: 1 fractional works · 1.3% of its workNeurology: 1 fractional works · 1.0% of its workSmaller subfields together: 0 fractional works · 0.4% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.8% of its workPharmaceutical Science: 0 fractional works · 0.5% of its workPharmacology: 0 fractional works · 0.3% of its workAgricultural and Biological Sciences: 0 fractional works · 0.3% of its workEcology, Evolution, Behavior and Systematics: 0 fractional works · 0.3% of its workSocial Sciences: 5 fractional works · 7.8% of its workEconomics, Econometrics and Finance: 4 fractional works · 6.3% of its workEconomics and Econometrics: 4 fractional works · 6.3% of its workBusiness, Management and Accounting: 1 fractional works · 1.1% of its workManagement of Technology and Innovation: 1 fractional works · 0.8% of its workAccounting: 0 fractional works · 0.3% of its workDecision Sciences: 0 fractional works · 0.3% of its workManagement Science and Operations Research: 0 fractional works · 0.3% of its workPsychology: 0 fractional works · 0.1% of its workPhysical Sciences: 2 fractional works · 3.4% of its workComputer Science: 1 fractional works · 1.8% of its workComputational Theory and Mathematics: 1 fractional works · 1.0% of its workComputer Vision and Pattern Recognition: 0 fractional works · 0.8% of its workMathematics: 1 fractional works · 0.9% of its workStatistics and Probability: 1 fractional works · 0.9% of its workEngineering: 0 fractional works · 0.6% of its workBiomedical Engineering: 0 fractional works · 0.3% of its workIndustrial and Manufacturing Engineering: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workChemistry: 0 fractional works · 0.2% of its workALL ITS WORKApellisPharmaceuticals…65fractional works, 2022-now
Life Sciences32%Physical Sciences3%Health Sciences56%Social Sciences8%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 16 fields, with their numbers
    1. Medicine3553.9%
    2. Health Professions22.4%
    3. Dentistry00.2%
    1. Immunology and Microbiology1421.8%
    2. Biochemistry, Genetics and Molecular Biology58.2%
    3. Neuroscience11.3%
    4. Pharmacology, Toxicology and Pharmaceutics00.8%
    5. Agricultural and Biological Sciences00.3%
    1. Economics, Econometrics and Finance46.3%
    2. Business, Management and Accounting11.1%
    3. Decision Sciences00.3%
    4. Psychology00.1%
    1. Computer Science11.8%
    2. Mathematics10.9%
    3. Engineering00.6%
    4. Chemistry00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.05× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.53× its world share, 5 worksBiochemistry, Geneti…Immunology and Microbiology: 21.68× its world share, 14 worksImmunology and Micro…Neuroscience: 0.81× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.17× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.11× its world share, 0 worksChemistryComputer Science: 0.23× its world share, 1 worksComputer ScienceEngineering: 0.04× its world share, 0 worksEngineeringMathematics: 0.74× its world share, 1 worksMathematicsDentistry: 0.35× its world share, 0 worksDentistryHealth Professions: 0.91× its world share, 2 worksHealth ProfessionsMedicine: 2.80× its world share, 35 worksMedicineBusiness, Management and Accounting: 0.34× its world share, 1 worksBusiness, Management…Decision Sciences: 0.26× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 2.94× its world share, 4 worksEconomics, Econometr…Psychology: 0.04× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 21.7×. Every wedge is a field page.

All 16 fields, with their numbers
  1. Immunology and Microbiology21.68×14 works
  2. Economics, Econometrics and Finance2.94×4 works
  3. Medicine2.80×35 works
  4. Pharmacology, Toxicology and Pharmaceutics2.17×0 works
  5. Biochemistry, Genetics and Molecular Biology1.53×5 works
  6. Health Professions0.91×2 works
  7. Neuroscience0.81×1 works
  8. Mathematics0.74×1 works
  9. Dentistry0.35×0 works
  10. Business, Management and Accounting0.34×1 works
  11. Decision Sciences0.26×0 works
  12. Computer Science0.23×1 works
  13. Chemistry0.11×0 works
  14. Agricultural and Biological Sciences0.05×0 works
  15. Engineering0.04×0 works
  16. Psychology0.04×0 works

Who are the top researchers at Apellis Pharmaceuticals (United States)?

Ranked on the quality score, Pascal Deschatelets, Cedric G. Francois and Alex S. McKeown lead among researchers whose main affiliation is Apellis Pharmaceuticals (United States).

  1. 1 Pascal Deschatelets United States · #307,753 worldwide 2.8k citations · 48 works
  2. 2 Cedric G. Francois United States · #701,260 worldwide 2.8k citations · 68 works
  3. 3 Alex S. McKeown United States · #913,310 worldwide 5.4k citations · 34 works
  4. 4 Temitayo Ajayi United States · #1,227,584 worldwide 2.8k citations · 75 works
  5. 5 Mohammed J Al-Adhami United States · #1,643,916 worldwide 996 citations · 74 works
  6. 6 Scott B. Baver United States · #1,666,713 worldwide 803 citations · 27 works
  7. 7 Crystal Chen United States · #1,746,163 worldwide 349 citations · 24 works
  8. 8 Delphine El Mehdi United States · #1,883,760 worldwide 785 citations · 16 works
  9. 9 Zhongshen Wang United States · #1,992,257 worldwide 143 citations · 23 works
  10. 10 Federico V. Grossi United States · #2,392,710 worldwide 2.5k citations · 124 works
All ranked researchers at Apellis Pharmaceuticals (United States)

What are the most cited papers from Apellis Pharmaceuticals (United States)?

The most cited paper from Apellis Pharmaceuticals (United States) is "Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration" (David S. Liao et al., 2019), with 527 citations. Next come "Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials" (509) and "Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria" (403).

Most cited papers
#PaperReleasedCitations
1 Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration David S. Liao et al. · Ophthalmology Open access 16 Jul 2019 527
2 Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials Jeffrey S. Heier et al. · The Lancet Open access263 authors Oct 2023 509
3 Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Peter Hillmen, Jeff Szer, Ilene Ceil Weitz et al. · New England Journal of Medicine Open access 17 Mar 2021 403
4 The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence–Based OCT Analysis Sophie Riedl, Wolf‐Dieter Vogl, Julia Mai et al. · Ophthalmology Retina Open access 3 Jun 2022 104
5 C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab Carlos de Castro, Federico V. Grossi, Ilene Ceil Weitz et al. · American Journal of Hematology Open access 28 Aug 2020 99
All 60 most cited papers, with filters and sorting

Which keywords describe research at Apellis Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Genetics, Innate Immunity, Regulation, Complement, Immune, Anemia, Macular Degeneration and Alloimmunization.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Genetics14▲ 29×7 topics
  2. Innate Immunity13▲ 63×3 topics
  3. Regulation13▲ 38×2 topics
  4. Complement13▲ 1120×1 topic
  5. Immune13▲ 1120×1 topic
  6. Inflammation6▲ 4.3×13 topics
  7. Epidemiology6▲ 2.1×18 topics
  8. Anemia5▲ 78×2 topics
  9. Macular Degeneration5▲ 59×3 topics
  10. Oxidative Stress5▲ 4.3×7 topics
  11. Alloimmunization4▲ 279×1 topic
  12. Blood Groups4▲ 279×1 topic
  13. Thrombosis4▲ 24×4 topics
  14. Quality of Life3▲ 3.6×4 topics
  15. Cost-effectiveness Analysis3▲ 63×1 topic
  16. Health Utility Measures3▲ 63×1 topic
  17. Vascular Endothelial Growth Factor3▲ 57×2 topics
  18. Diabetic Retinopathy3▲ 48×2 topics
  19. Hereditary Angioedema3▲ 261×1 topic
  20. Kinin Receptor Family3▲ 261×1 topic
  21. Glomerular Diseases3▲ 142×1 topic
  22. Nephrotic Syndrome3▲ 142×1 topic
  23. Pulmonary Hypertension3▲ 33×3 topics
  24. Choroidal Thickness3▲ 80×1 topic
  25. Retinal Pigment Epithelium3▲ 80×1 topic
  26. Sickle-cell Disease3▲ 109×1 topic
  27. Thalassemia3▲ 109×1 topic
  28. Gene Therapy2▲ 17×5 topics
  29. Hepatic Encephalopathy2▲ 56×1 topic
  30. Liver Cirrhosis2▲ 56×1 topic
  31. Neurodegeneration2▲ 8.1×5 topics
  32. Retinal Stem Cells2▲ 109×1 topic
  33. Retinitis Pigmentosa2▲ 109×1 topic
  34. Occupational Safety2▲ 25×1 topic
  35. Safety Culture2▲ 34×1 topic
  36. Glaucoma1▲ 13×2 topics
  37. Optic Nerve1▲ 20×2 topics
  38. Hemostasis1▲ 18×2 topics
  39. Myopia1▲ 27×2 topics
  40. Optical Coherence Tomography1▲ 19×3 topics

Which research topics does Apellis Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Complement system in diseases, Blood groups and transfusion, Health Systems, Economic Evaluations, Quality of Life and Coagulation, Bradykinin, Polyphosphates, and Angioedema.

Complement system in dis…13Complement system in diseases: 13 fractional worksBlood groups and transfu…4Blood groups and transfusion: 4 fractional worksHealth Systems, Economic…3Health Systems, Economic Evaluations, Quality of Life: 3 fractional worksCoagulation, Bradykinin, Polyphosphates, and Angioedema: 3 fractional worksRenal Diseases and Glomerulopathies: 3 fractional worksHemoglobinopathies and R…3Hemoglobinopathies and Related Disorders: 3 fractional worksRetinal Diseases and Treatments: 3 fractional worksLiver Disease and Transplantation: 2 fractional worksRetinal Development and Disorders: 2 fractional worksOccupational Health and Safety Research: 2 fractional works
ImmunologyHematologyEconomics and EconometricsGenetics5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Complement system in diseases Immunology 13 works
  2. 2 Blood groups and transfusion Hematology 4 works
  3. 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 3 works
  4. 4 Coagulation, Bradykinin, Polyphosphates, and Angioedema Genetics 3 works
  5. 5 Renal Diseases and Glomerulopathies Nephrology 3 works
  6. 6 Hemoglobinopathies and Related Disorders Genetics 3 works
  7. 7 Retinal Diseases and Treatments Ophthalmology 3 works
  8. 8 Liver Disease and Transplantation Hepatology 2 works
  9. 9 Retinal Development and Disorders Molecular Biology 2 works
  10. 10 Occupational Health and Safety Research Radiological and Ultrasound Technology 2 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available54.0%not open46.0%

World: 40% of research is openly available.

with international co-authors34.5%domestic only65.5%

World: 18% is written across borders.

How has Apellis Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 245% higher than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Apellis Pharmaceuticals (United States) as a percentage of every work published that year, 0.00026% in 2024.

still counting0.00020%0.00040%Apellis Pharmaceuticals (United States)0.00017% in 2025200020102020

Fractional works of Apellis Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Waltham

All research institutions in Waltham

Share Apellis Pharmaceuticals (United States)'s ranking

Apellis Pharmaceuticals (United States) on Science Explorer

A card with Apellis Pharmaceuticals (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Apellis Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.